Review of non-invasive testing (NIT) strategies for identifying fibrotic MASH candidates and monitoring treatment response following the FDA approvals of resmetirom and semaglutide, highlighting inadequacies of existing NITs for patient selection. Evaluates novel biomarkers and imaging tools that may replace liver biopsy as the standard for MASH staging and drug monitoring. Provides a practical framework for implementing NITs in the post-approval era—addressing the urgent clinical need to identify semaglutide-eligible MASH patients without requiring invasive histological assessment.
Theocharidou, Eleni; Germanidis, Georgios